Navigation Links
White House Highlights Innovative Arthritis Research

ATLANTA, June 20, 2013 /PRNewswire-USNewswire/ -- The White House Office of Science and Technology Policy will highlight innovative arthritis research at an event today honoring "Open Science Champions of Change." Dr. Stephen Friend, president of Sage Bionetworks, will be recognized at the event for innovative research projects such as the Rheumatoid Arthritis Responder Challenge, a collaborative genomics study that will use open scientific data and publications to accelerate progress in rheumatoid arthritis, sponsored in part by the Arthritis Foundation.

Rheumatoid arthritis is a chronic autoimmune disease that affects 1.5 million Americans and can lead to long-term joint damage. Currently, up to one-third of rheumatoid arthritis patients do not respond to rheumatoid arthritis treatment after a standard course of therapy and there are no existing genetic predictors to identify who will and will not respond to a particular therapy.

"Innovative research collaborations such as the Rheumatoid Arthritis Responder Challenge will help predict the best therapy as we work toward a goal of personalized medicine for rheumatoid arthritis," said Arthritis Foundation Vice President of Research, John Vernachio, Ph.D. "We are excited about gaining genetic insight from the Challenge and applying those findings to citizen scientists enrolled in an existing  Arthritis Internet Registry."

Expediting Treatments Through Challenges
Challenges have been used successfully in other research fields, and for the past six years the DREAM project has organized a series of Challenges in systems biology intended to advance the field by organizing multiple groups to attack the same problems from different angles. Earlier this year, DREAM and Sage Bionetworks merged their efforts to work on future DREAM Challenges together and take them to a new level of operation and impact.

"The Rheumatoid Arthritis Responder Challenge represents a unique interaction among an international team of researchers from academics and industry who share a common goal: improve the lives of patients with a debilitating form of arthritis," said Director of Genetics & Genomics at Brigham & Women's Hospital, Dr. Robert Plenge. "We will make complex genetic and genomic datasets available to researchers from across the world through a unique computing platform developed by Sage Bionetworks.  By leveraging the power of the crowd, we hope to solve a vexing clinical problem about predicting which patients will respond to an expensive and potentially dangerous medication, anti-TNF therapy."

A unique component of the Rheumatoid Arthritis Responder Challenge is the diversity of participation across a number of groups from academic institutions, private foundations and for-profit companies.  The funding and support to carry out the Challenge and to support Sage Bionetworks' cloud-based data analysis platform (Synapse) where the Challenge will take place, derives from the Arthritis Foundation and several major pharmaceutical companies.  Additional support for the Challenge comes from data and samples contributed by the Consortium of Rheumatology Researchers of North America, Inc. (CORRONA), the National Institutes of Health Pharmacogenomics Research Network (PGRN), the Broad Institute, and academic researchers from across the world.  For example, CORRONA is providing unique clinical samples from a prospective study of rheumatoid arthritis patients treated with anti-TNF therapy, and the PGRN is supporting the genotyping of these samples for the Challenge itself.

"The Consortium of Rheumatology Researchers of North America (CORRONA) is very pleased to contribute the validation cohort of rheumatoid arthritis patient samples who were prescribed anti-TNF biologic drugs," said Jeff Greenberg, MD, MPH, Chief Scientific Officer of CORRONA.  "The challenges of pharmacogenetic research and personalized medicine for rheumatoid arthritis patients require innovative and highly collaborative research teams to improve patient outcomes."

The Challenge will open this fall and complete in the winter of 2014. The first phase of the challenge is a discovery phase in which teams use the data to build genetic predictors of response to anti-TNF therapy. The second phase is a validation assessment in which challenge participants' predictive models will be tested against a newly generated rheumatoid arthritis dataset (from CORRONA). The team with the most highly predictive model in the validation assessment will be deemed the "winner."  The results of the challenge will be published in a highlighted article as a collaborative effort with Nature Genetics.  The winning classifier will potentially be used to drive a prospective clinical trial with materials and data collected through the Arthritis Internet Registry.

"Sage Bionetworks/DREAM are delighted to be in lockstep on this challenge with the Arthritis Foundation," said President of Sage Bionetworks, Dr. Stephen Friend.  "Their support for a prospective clinical trial to evaluate the winning model highlights the Arthritis Foundation's leading role in the development of impactful, precision medicine approaches to health."

To help researchers find more effective treatments and potentially a cure for arthritis, the Arthritis Foundation is calling on people living with rheumatic conditions to join the Arthritis Internet Registry. For more information and to register, click here.

About the Arthritis Foundation
Striking one in every five adults and 300,000 children, arthritis is the nation's leading cause of disability.  The Arthritis Foundation ( is committed to raising awareness and reducing the unacceptable impact of this serious and painful disease, which can severely damage joints and rob people of living life to its fullest.  The Foundation funds life-changing research that has restored mobility in patients for more than six decades; fights for health care policies that improve the lives of the millions who live with arthritis; and partners with families to provide empowering programs and information.

About Sage Bionetworks
Sage Bionetworks is a nonprofit biomedical research organization, founded in 2009, with a vision to promote innovations in personalized medicine by enabling a community-based approach to scientific inquiries and discoveries.  Sage Bionetworks Bionetworks strives to activate patients and to incentivize scientists, funders and researchers to work in fundamentally new ways in order to shape research, accelerate access to knowledge and transform human health. 

Sage Bionetworks is located on the campus of the Fred Hutchinson Cancer Research Center in Seattle, Washington and is supported through a portfolio of philanthropic donations, competitive research grants, and commercial partnerships. More information is available at http://Sage

SOURCE Arthritis Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. White House S&T advisor the Honorable Dr. John Holdren tours Naval Research Laboratory
2. White LEDs directly on paper
3. Labcon Attends White House Business Council Forum on American Manufacturing Competitiveness
4. White Mountain Process Introduces Squeal-less Mechanical Seal
5. Autoimmune disease retraining white blood cells
6. Prizmatix Introduces Ultra High Power LED with Over 4 Watts of Collimated White Light for Scientific and Industrial Applications
7. 100% Identification of Defective Blister Packs by Sepha's VisionsScan According to New Whitepaper
8. Tote Mixers In 48 Hours From White Mountain Process Mixers, Agitators & Blenders
9. Israel’s BioEnergy Leaders Meet for Two Days of Deliberations with U.S. Government Counterparts - Following Wednesday White House Briefing
10. RURO Releases New White Paper on Creating the Modern Lab
11. White Mountain Process Announces Sanitary Autoclave Style Pharmaceutical Agitator
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  ATCC, the premier global ... it has been selected by The Michael J. Fox ... lines to academic, pharmaceutical, and biotechnology organizations committed to ... the United States , and more than ... the United States , and more than ...
(Date:10/8/2015)... Maryland , October 8, 2015 ... .   --> Goldman Small ... in the small cap and microcap sectors, announced ... research report on PharmaCyte Biotech, Inc. (OTCQB - ... focused on developing and preparing treatments for cancer ...
(Date:10/8/2015)... 8, 2015  Today, DuPont and Caribou Biosciences, ... editing, jointly announced a strategic alliance. As part ... respective patent portfolios, with DuPont receiving exclusive intellectual ... row crops, and non-exclusive rights in other agricultural ... --> --> In addition, the ...
(Date:10/8/2015)... Oct. 8, 2015  Today the Wyss Institute for ... of its start-up company Opsonix Inc. The ... Harvard,s Office of Technology Development (OTD) and Opsonix ... therapy for clinical use. --> ... a million people every year in the U.S. — ...
Breaking Biology Technology:
... (Amex: PLX ), announced today that it ... its manufacturing and research,facility. The expanded space, located ... the Company with approximately three times its current,manufacturing ... Company,s lead product candidate, prGCD, a therapeutic protein ...
... The Woodbridge Group announced,the most extensive interior ... "Green" Polyurethane Foams. As a key component ... technology, substitutes petroleum,with plant oils, in the ... a full line-up of automotive interior,applications includes; ...
... Pharmaceuticals,Inc. (NYSE: BRL ) today confirmed that ... of the patent listed by Forest,Laboratories, Inc. in ... 10mg., Barr filed its Abbreviated New Drug ... generic Namenda product with the U.S. Food,& Drug ...
Cached Biology Technology:
(Date:9/28/2015)... , Sept. 28, 2015 Synaptics Inc. ... interface solutions, today announced that Lenovo has selected Synaptics ... sensor, FS4202, for its latest smartphone, the Vibe P1. ... access to unlock the device and provide swift access ... The feature-rich Natural ID FS4202 sensor solution utilizes ...
(Date:9/24/2015)... 2015  EyeLock LLC, a market leader of iris-based ... and latest technology in Booth #602 at next week,s ... EyeLock,s iris authentication technology provides an unprecedented ... making it the most proven way to authenticate one,s ... to deliver a fast and friendly user experience to ...
(Date:9/10/2015)... This report provides detailed descriptions of the ... emerging sensor types that will dominate in the future. ... the wearable technology hype curve in the last five ... feature with all of them is the prominence of ... useful functions. Sensors collect data about the physical and ...
Breaking Biology News(10 mins):
... Amsterdam, 16 March, 2011 A recent special edition ... Elsevier, on behalf of the British Mycological Society, features a ... collection of fungal cell biology movies ever published. The movies ... Exeter, UK, who is a renowned researcher in the field ...
... analyze the complex ingredients in the new genre of ... for cigarettes in places where smoking is banned have ... The report appears in ACS,s Journal of Agricultural ... colleagues point out that the first dissolvable tobacco products ...
... Trends in Plant Science , provides an overview ... for ecologists, physiologists and molecular biologists, since it covers ... change. The results show that plants in ... to a changing environment without requiring any evolutionary changes, ...
Cached Biology News:
... 20 Plasma Immunodepletion Kit specifically removes 20 ... plasma or serum in preparation for further ... into the plasma proteome whether you use ... chromatography or go straight to mass spectrometry. ...
... Since OligoEngine introduced the industry's first ... have constantly strived to keep these tools ... research reports in the field of RNAi. ... enhanced, and expanded RNAi design tools, OligoEngine ...
... for enzyme-/substrate-based blotting what intensifying screens do for ... to 10-fold (or one order of magnitude) in ... Enhancer membrane treatment is a simple, 15-minute procedure ... Western blotting protocol. The result is an increase ...
Biology Products: